This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Dr. Gbenga Ogedegbe In this Friday’s PCT Grand Rounds, Gbenga Ogedegbe of the NYU Grossman School of Medicine will present “Home Blood Pressure Telemonitoring and Nurse Case Management in Black and Hispanic Patients With Stroke: A Randomized Clinical Trial.” The Grand Rounds session will be held on Friday, December 13, 2024, at 1:00 pm eastern.
The biopharmaceutical industry has witnessed a significant surge in the number of therapeutic molecules in development, leading to a corresponding increase in the number of contract development and manufacturing organizations (CDMOs). This growth has created a competitive landscape where pharmaceutical companies must carefully evaluate and select the right CDMO partner to ensure the success of their projects.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
The pharmaceutical industry, particularly the generic drug sector, faces significant challenges in adopting sustainable practices. As the world grapples with the consequences of climate change, companies must adapt their operations to reduce environmental impacts while maintaining cost-effectiveness and regulatory compliance. This article outlines key considerations and strategies for developing a sustainable generic drug development strategy.
Youve probably heard it all before: The clinical research enterprise has a problem with expecting new hires in what are often basically low-paying, entry-level positions to already have two or more years of experience with the positions duties. Its a talent acquisition model that does no one any favors, especially at the study site level where a healthy pipeline of new clinical research coordinators (CRCs) would go a long way to alleviating delays in trial conduct.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
In this episode, Ayesha spoke with Jonathan Rigby, MBA, CEO of Sernova , a Canadian biotech company developing innovative cell therapy-based approaches for the management of type 1 diabetes. The companys lead innovation is an implantable bio-hybrid organ pouch, which is currently in an ongoing Phase I/II clinical trial. An estimated 537 million people are currently living with diabetes globally and this number is projected to reach 643 million by 2030, making it a pressing health issue in need o
The prevailing treatment paradigm for newly diagnosed multiple myeloma (NDMM) patients who have received autologous stem cell transplantation (SCT) primarily consists of chemotherapy or Johnson & Johnsons (J&J) Darzalex in combination with chemotherapy.
Today, the U.S. Food and Drug Administration (FDA) and the Clinical Trials Transformation Initiative (CTTI) announced eight newly selected representatives for the Patient Engagement Collaborative (PEC). The group of 16 caregivers, patients, and patient group representatives meets with the FDA several times a year and discusses a variety of topics such as improving communications, education, and patient engagement related to medical product regulation.
Event type: webinar Audience: general public health professionals journalist PhD students policy makers representatives of care and professional organisations scientists university staff Description: The COVID -19 pandemic has had a profound impact on the mental and physical health and family dynamics of children and young adults in Belgium. Scientific research shows that they have faced unique challenges ranging from interrupted education and socialization to increased stress and anxiety.
Compliance with the Drug Supply Chain Security Act (DSCSA) is crucial to ensure a secure and efficient pharmaceutical supply chain. Industry experts share strategies for implementing serialized data tracking, overcoming compliance challenges, and fostering collaboration across the supply chain to maintain operational efficiency and patient safety.
Its dj vu for Siga Technologies and its smallpox antiviral Tpoxx. At an interim analysis of a second mpox trial, the drug again missed the mark on a key measure of disease resolution. | The antiviral didn't demonstrate efficacy in patients with the clade 2 mpox strain, matching August results in patients with clade 1 mpox.
In a new pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Dr Victoria Richon, CEO of Entact Bio, a company focused on the small molecule space, with its team of scientists, entrepreneurs, drug creators, and problem solvers working together to bring new medicines to patients who currently have few options.
AbbVie has announced encouraging topline results from its Phase III TEMPO-2 clinical trial, evaluating tavapadon as a monotherapy for early Parkinsons disease. The trial met its primary and key secondary endpoints, demonstrating significant improvements in motor and daily living functions. These findings underscore tavapadons potential as a first-in-class treatment option, addressing unmet needs with strong efficacy and manageable side effects.
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Speaker Michael E. Matheny, MD, MS, MPH Director, Center for Improving the Publics Health Through Informatics Professor of Biomedical Informatics, Biostatistics, and Medicine Vanderbilt University Medical Center Staff Scientist, Geriatrics Research Education and Clinical Care Service Associate Director, VA ORD VINCI Tennessee Valley Healthcare System VA Slides Keywords Artificial Intelligence; Large Language Models; Surveillance; Medical Products Key Points Increasingly
Achieving operational excellence in a Contract Development and Manufacturing Organization (CDMO) is crucial to ensure the quality and consistency of products and services. This can be achieved by implementing robust controls, optimizing workflows, and fostering a culture of continuous improvement. Here are some key strategies to achieve operational excellence in a CDMO: Implementing Robust Controls Compliance with Regulatory Guidelines : Ensure compliance with strict regulatory standards set by
Great Talent Deserves a Great Workplace! In this season of gratitude, were especially thankful for our global team, whose relentless pursuit of improving healthcare inspires us daily. From identifying undiagnosed patients to introducing new therapies, their innovation is transformative. Recently, we asked our team why they voted us a Great Place To Work and what drives them to excel.
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
144 
Let's personalize your content